Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study

Next Previous
Trial Profile

EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary) ; Atorvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms EVOPACS

    • Most Recent Events

    • 28 Aug 2023 Results assessing the impact of evolocumab on platelet function in ACS patients receiving potent antiplatelet therapy, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 26 Aug 2023 According to an Amgen media release, data this study of olpasiran, presented in a late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam.
    • 16 Aug 2019 Primary endpoint (Percent change in calculated LDL-C in the intent to treat (ITT) population) has been met as per results published in the Journal of the American College of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top